Physician

Ali Mohammed, M.D.

According to 2025 Medicare claims, Ali Mohammed, M.D. (NPI: 1396735940) practices nephrology in the Flint, MI market, with the plurality of this provider's patient population coming from Genesee, MI. This provider's primary affiliated billing organization is NEPHROLOGY & INTERNAL MEDICINE PC (NPI: 1730190596; TIN: 381855757) and primary practice location at 48439-8065. Mohammed is affiliated with the McLaren High Performance Network, LLC (ACO ID: A3317), participating under the MSSP model.

Mohammed's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 620 traditional Medicare patients, billed 2,163 HCPCS/CPT codes, and received $257,281 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 6,351 prescription claims across 1,064 beneficiaries totaling $507,957 in drug costs, led by Jardiance (Empagliflozin). DME data shows 346 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $529,994 to $257,281. Similarly, Part D prescription costs have declined steadily, from $795,431 to $507,957. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,115	5,131	$529,994
2016	1,051	4,545	$482,482
2017	1,074	4,598	$472,274
2018	911	4,241	$428,336
2019	906	4,166	$433,268
2020	789	3,196	$355,177
2021	732	2,869	$379,990
2022	702	2,765	$340,873
2023	658	2,509	$287,868
2024	620	2,163	$257,281

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	851	5,807	$795,431
2016	846	5,398	$648,005
2017	822	5,257	$592,472
2018	836	5,350	$597,876
2019	923	5,908	$470,583
2020	922	6,052	$600,635
2021	947	5,759	$475,064
2022	1,018	5,705	$418,518
2023	1,022	6,088	$478,459
2024	1,064	6,351	$507,957

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	40	502	$33,539
2016	27	468	$24,079
2017	37	587	$24,960
2018	39	655	$32,392
2019	56	771	$29,236
2020	58	815	$32,711
2021	49	628	$22,899
2022	N/R	389	$11,091
2023	N/R	379	$8,423
2024	N/R	346	$7,127

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	97	101	$131
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	188	272	$97
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	86	140	$91
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	235	327	$75
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	178	528	$59

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	91	5,430	$101,567
Farxiga	Dapagliflozin Propanediol	61	3,280	$59,725
Rayaldee	Calcifediol	36	1,134	$38,395
Kerendia	Finerenone	18	1,320	$26,113
Lokelma	Sodium Zirconium Cyclosilicate	39	1,945	$25,474

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	77	$1,994
J7515	Cyclosporine, oral, 25 mg	N	N/R	13	$1,552
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	79	$1,412
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	95	$1,191
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	56	$959

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Ali Mohammed, M.D.?

Tedicare shows public-source Medicare data for Ali Mohammed, M.D. (NPI 1396735940), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ali Mohammed, M.D. have ACO affiliation data?

Ali Mohammed, M.D. is shown with ACO affiliation data for McLaren High Performance Network, LLC (MSSP, ACO ID A3317).

What billing organization is linked to Ali Mohammed, M.D.?

Ali Mohammed, M.D. is linked to NEPHROLOGY & INTERNAL MEDICINE PC (billing NPI 1730190596) in the available physician profile data.

Does Ali Mohammed, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.